Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 1/20 | 0.64 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.57 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11237589 | 1.00 | THRA (0.67) | THRATHRBPPARGPPARAPTPN11 | |
| SCHEMBL1750021 | 0.96 | PPARG (0.61) | THRATHRBPPARGPPARAPTPN11 | |
| SCHEMBL5492191 | 0.93 | PTPN11 (0.64) | THRATHRBPTPN11PLA2G2ATP53 | |
| SCHEMBL7820620 | 0.93 | PTPN11 (0.64) | THRATHRBPTPN11PLA2G2ATP53 | |
| SCHEMBL8902012 | 0.90 | THRA (0.54) | THRATHRBPPARGPPARAPTPN11 | |
| SCHEMBL2454085 | 0.88 | PPARG (0.56) | THRATHRBPPARGPPARAPTPN11 | |
| SCHEMBL1750042 | 0.88 | PTPN11 (0.57) | THRATHRBPPARGPPARAPTPN11 | |
| SCHEMBL20919872 | 0.86 | PTPN11 (0.57) | THRATHRBPTPN11PLA2G2ATP53 | |
| SCHEMBL4518420 | 0.86 | PTPN11 (0.61) | THRATHRBPTPN11TP53TSHR | |
| SCHEMBL29688035 | 0.85 | THRA (0.61) | THRATHRBPTPN11PLA2G2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | THRA 1548/4885THRB 1355/4885PPARG 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.